Table 2.

Summary of clinical trails with moexipril

Author (n = no. pts)		Drug (mg)	Change in SDBP from baseline (mmHg)	Duration (weeks)
Comparative studies
	Persson (n = 201) (1996)	MO 7.5 od	−8.7	8
		MO 15 od	−10.1	8
		HCTZ 25 od	−10.5	8
	Stimpel, Oparil (n = 97) (1998)	MO 15 od	−10.0	12
		HCTZ 25 od	−11.8	12
	Stimpel, Webera(n = 116) (1998)	MO 15 od	−10.0	8
		ATE 50 od	−8.4	8
	Abernethy (n = 178) (1995)	MO 75–15 od	−10.0	24
		VER-SR 180–240 od	−11.0	24
	Stimpel (n = 159) (1996a)	MO 7.5–15 od	−9.8	12
		CAP 25–50 BID	−8.7	12
	Agabiti-Rosei (n = 93) (1999)	MO 15 od	−15.2	8
		NIT 20 od	−13.6	8
Add-on studies
	Chrysantb (n = 147) (1995)	MO 7.5–15 od	−11.0	12
		VER-SR 180–240 od	−12.0	12
	Dicksteinb (n = 200) (1994)	MO 3.75 od	−8.4	8
		MO 7.5 od	−8.8	8
		MO 15 od	−8.9	8
		PL od	−4.6	8
	Perssonc (n = 203) (1996)	MO 3.75 od	−6.0	8
		MO 7.5 od	−9.0	8
		MO 15 od	−9.0	8
		PL od	−5.0	8
Fixed combination studies
	White (n = 272) (1997)	MO 15 od	−8.0	12
		MO 30 od	−9.7	12
		HCTZ 25 od	−8.1	12
		HCTZ 50 od	−11.0	12
		MO/HCTZ 15/25 od	−16.0	12
		MO/HCTZ 30/50 od	−17.9	12
	Chrysant (n = 223) (1998)	MO/HCTZ 3.75/6.25 od	−7.6	12
		PL od	−3.9	12
	Stimpel (n = 140) (1997)	MO/HCTZ 7.5/12.5 od	−12.8	12
		MET/HCTZ 100/12.5 od	−13.9	12
Open label long-term studies
	White (n = 172) (1995)	MO 7.5–15 od	−14.0	52
		MO/HCTZ 7.5–15/25 od	−17.0	52
	White (n = 281) (1994)	MO 7.5–30 od	−14.0	52
		MO/HCTZ 7.5–30/12.5 od	−15.0	52

^aHCTZ 25 mg od was added if necessary.

^bHCTZ 25 mg background-therapy.

^cNifedipine 20 mg background-therapy.

Abbreviations: ATE, atenolol; CAP, captopril; HCTZ, hydrochlorothiazide; MET, metoprolol; MO, moexipril; NIT, nitrendipine;VER-SR, verapamil SR.